

### **India | Equities**

# Cement Company Update

Change in Estimates ☑ Target ☑ Reco□

21 June 2020

# **Ramco Cements**

Operating efficiency to improve; expansions would help; Buy

The Covid'19-compelled lockdown from Mar'20 hurt Ramco's Q4. Its revenue/EBITDA/PAT declined 9%/15%/12%. The Vishakhapatnam expansion was completed in Mar. Labour unavailability, however, delayed the remaining expansions by 3-5 months. With demand in the near term expected to be sluggish, we expect profitability to improve on steady pricing, lower fuel prices and new capacity commissioning. We maintain our Buy rating, with a higher target price of ₹748 (earlier ₹683).

Volume dip on lockdown. The company reported an 11% volume decline on lost business days due to the lockdown in Mar'20, leading revenue to dip 9% y/y to ₹13.8bn. On firm prices, however, realisation grew 1.6% y/y. Prices are expected to be firm because of low industry utilisation, whereas volumes are expected to dip 10% in FY21. However, backed by expected government spending on infrastructure for employment generation and by commissioning of new capacities, we expect FY22 volumes to grow 17.4% y/y.

Operating efficiency to improve. EBITDA/ton dipped 4.7% y/y to ₹924 (₹695 the quarter prior, ₹970 a year ago). Softer fuel costs helped: power & fuel cost/ton and freight cost/ton dipped 2.8% and 1.3% y/y. The company is expected to further benefit from falling fuel prices on the commissioning of the WHRS, lower petcoke prices and optimising the supply chain. We expect EBITDA/ton of ₹911 and ₹1,071 in FY21and FY22 (vs ₹940 in FY20)

Outlook, Valuations. The 1.05m-ton GU expansion at Vishakhapatnam was commissioned in Mar'20. However, labour availability delayed the expansion at Odisha and Jayanthipuram by 3-5 months; the expansion at Kurnool will be complete by Mar'21. On 31st Mar'20 gross debt increased to ₹30.24bn (vs ₹26.8bn at end-Dec'19). The company has so far incurred ₹19.2bn on ongoing expansions. With the balance capex of ₹13.8bn, we expect the leverage to be high with a net D/E of 0.7x in FY21. We maintain a Buy rating, with a higher target price of ₹748 (earlier ₹683), based on 16x FY22e EV/ EBITDA. Risks: Extension of the lockdown; rise in pet-coke/diesel costs.


FY18	FY19	FY20	FY21e	FY22e
43,181	50,602	52,854	49,255	59,131
5,557	5,059	6,011	4,195	6,372
23.6	21.5	25.5	17.8	27.0
31.1	34.3	20.1	36.2	23.8
18.1	19.9	14.3	20.2	14.1
143.9	148.6	104.7	117.5	113.0
14.3	11.9	12.8	8.2	11.4
8.6	7.2	7.1	4.5	6.4
0.4	0.4	0.5	0.3	0.3
0.2	0.3	0.6	0.7	0.5
	43,181 5,557 23.6 31.1 18.1 143.9 14.3 8.6 0.4	43,181         50,602           5,557         5,059           23.6         21.5           31.1         34.3           18.1         19.9           143.9         148.6           14.3         11.9           8.6         7.2           0.4         0.4	43,181         50,602         52,854           5,557         5,059         6,011           23.6         21.5         25.5           31.1         34.3         20.1           18.1         19.9         14.3           143.9         148.6         104.7           14.3         11.9         12.8           8.6         7.2         7.1           0.4         0.4         0.5	43,181         50,602         52,854         49,255           5,557         5,059         6,011         4,195           23.6         21.5         25.5         17.8           31.1         34.3         20.1         36.2           18.1         19.9         14.3         20.2           143.9         148.6         104.7         117.5           14.3         11.9         12.8         8.2           8.6         7.2         7.1         4.5           0.4         0.4         0.5         0.3

Rating: **Buy**Target Price: ₹748
Share Price: ₹645

Key data	TRCL IN / MSCM.BO
52-week high / low	₹884 / 455
Sensex / Nifty	34732 / 10244
3-m average volume	\$6.3m
Market cap	₹152bn / \$1993.5m
Shares outstanding	236m

Shareholding pattern (%)	Mar'20	Dec'19	Sep'19
Promoters	42.7	42.7	42.7
- of which, Pledged	2.0	2.0	2.0
Free float	57.3	57.3	57.3
- Foreign institutions	8.9	11.7	11.7
- Domestic institutions	24.5	21.9	21.6
- Public	24.0	23.7	24.0

Estimates revision (%)	FY21e	FY22e
Sales	(2.8)	0.4
EBITDA	0.4	6.6
PAT	2.6	7.6



Manish Valecha Research Analyst

> Vibha Jain Research Asociate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

# **Quick Glance – Financials and Valuations**

Fig 1 – Income state	ment (₹ r	n)			
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e
Sales volumes (m tons)	9.3	11.1	11.2	10.1	11.9
Net revenues	43,181	50,602	52,854	49,255	59,131
Growth (%)	11.96	17.19	4.45	-6.81	20.05
Direct costs	24,077.5	30,921.7	30,625.3	27,469.1	32,879.6
SG&A	8,992	10,176	11,693	12,572	13,534
EBITDA	10,112	9,505	10,536	9,214	12,717
EBITDA margins (%)	23.4	18.8	19.9	18.7	21.5
- Depreciation	2,922	2,985	3,153	3,635	4,445
Other income	1,249	1,145	1,202	1,040	1,215
Interest expenses	592	509	714	1,025	990
PBT	7,847	7,156	7,872	5,593	8,497
Effective tax rate (%)	29.18	29.30	23.64	25.00	25.00
+ Associates / (Minorities)	-	-	-	-	-
Net income	5,557	5,059	6,011	4,195	6,372
Adjusted income	5,557	5,059	6,011	4,195	6,372
WANS	236	236	236	236	236
FDEPS (₹ / sh)	23.6	21.5	25.5	17.8	27.0
FDEPS growth (%)	-13.55	-8.96	18.82	-30.21	51.91


Fig 3 – Cash-flow statement (₹ m)											
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e						
PBT	7,847	7,156	7,872	5,593	8,497						
+ Non-cash items	2,922	2,985	3,153	3,635	4,445						
Oper. prof. before WC	10,769	10,141	11,025	9,228	12,942						
- Incr. / (decr.) in WC	-1,615	2,899	2,591	-1,320	1,163						
Others incl. taxes	1,997	1,846	1,025	1,298	2,024						
Operating cash-flow	10,387	5,396	7,409	9,250	9,754						
- Capex (tang. + intang.)	4,650	10,369	19,701	13,800	2,000						
Free cash-flow	5,736	-4,973	-12,292	-4,550	7,754						
Acquisitions											
- Div. (incl. buyback & taxes)	2,534	853	711	471	471						
+ Equity raised	-	-	-	-	-						
+ Debt raised	-3,117	5,055	14,054	5,000	-7,000						
- Fin investments	79	326	-19	-	-						
- Misc. (CFI + CFF)	-6	-830	1,084	100	100						
Net cash-flow	13	-267	-13	-121	183						
Source: Company, Anand Rathi Res	earch										

Fig	5 -	- P	ric	е	mo	νe	m	en	t														
(₹) 900																	TR	101					
800																	II	IUL I	٨		A	M	
700																	A	الها	4	١.,	11		
600															L	N			Г	W			1
500															ľ	4							-
400													_	e di	1								
300											N	W	W										
200							_ 1	محو	1	W													
100	M	~~	~	My	~	لبر	~																
0	6	0	0	0			ΩI.	ΩI.	m	က	₹	< +	LC.	LC.		(0	_	_	ω.	ω.	0		
	Juno	Dec-0	Jun-1	Dec-1	Jun-1	Dec-1	Jun-1	Dec-1	Jun-1;	Dec-1;	Jun-1	Dec-1	Jun-1	Dec-1	Jun-1	Dec-1	Jun-1	Dec-1	Jun-1	Dec-1	Jun-1	Dec-19	Jun-2
Sourc	ce: l	ВІоо	mb	erg																			

Fig 2 - Balance shee	et (₹m)				
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e
Share capital	236	236	236	236	236
Net worth	40,422	44,601	49,186	52,909	58,811
Debt	11,132	16,187	30,241	35,241	28,241
Minority interest	-	-	-	-	-
DTL / (Assets)	7,597	8,704	9,172	9,172	9,172
Capital employed	59,150	69,493	88,599	97,322	96,224
Net tangible assets	50,088	50,664	57,316	84,885	82,940
Net intangible assets	518	549	567	567	567
Goodwill	-	-	-	-	-
CWIP (tang. &intang.)	1,749	8,526	18,404	1,000	500
Investments (strategic)	3,963	4,289	4,270	4,270	4,270
Investments (financial)	5	5	5	5	5
Current assets (ex cash)	13,387	4,698	18,994	17,408	20,898
Cash	1,194	928	914	793	976
Current liabilities	11,754	11,590	11,871	11,605	13,932
Working capital	1,633	4,532	7,123	5,803	6,966
Capital deployed	59,150	69,493	88,599	97,322	96,224
Contingent liabilities	10967	9876	-	-	-

Fig 4 – Ratio analysis					
Year-end: Mar	FY18	FY19	FY20	FY21e	FY22e
P/E (x)	31.1	34.3	20.1	36.2	23.8
EV / EBITDA (x)	18.1	19.9	14.3	20.2	14.1
EV / Sales (x)	4.2	3.7	2.8	3.8	3.0
P/B (x)	4.3	3.9	2.5	2.9	2.6
RoE (%)	14.3	11.9	12.8	8.2	11.4
RoCE (%) - after tax	8.6	7.2	7.1	4.5	6.4
DPS (₹ / sh)	3.0	3.0	2.5	2.0	2.0
Dividend payout (%) - incl. DDT	45.6	16.9	11.8	11.2	7.4
Net debt / equity (x)	0.2	0.3	0.6	0.7	0.5
WC days	13.8	32.7	49.2	43.0	43.0
EV / ton (\$)	143.9	148.6	104.7	117.5	113.0
NSR / ton (₹)	4,637	4,551	4,718	4,868	4,978
EBITDA / ton (₹)	1,086	855	940	911	1,071
Volumes (m tons)	9.31	11.12	11.20	10.12	11.88
CFO: PAT (%)	186.9	106.7	123.3	220.5	153.1
Source: Company, Anand Rathi Resea	rch				





# **Result Highlights**

Fig 7 – Quarterly po	erforman	ce											
(₹ m)	Q2 FY18	Q3 FY18	Q4 FY18	Q1 FY19	Q2 FY19	Q3 FY19	Q4 FY19	Q1 FY20	Q2 FY20	Q3 FY20	Q4 FY20	% Y/Y	% Q/Q
Sales	10,293	10,475	12,508	11,860	11,413	12,065	15,265	13,486	12,824	12,728	13,817	-9.5	8.6
EBITDA	2,568	2,264	2,682	2,164	2,049	2,101	3,192	3,240	2,609	1,977	2,711	-15.1	37.1
EBITDA margins (%)	24.9	21.6	21.4	18.2	18.0	17.4	20.9	24.0	20.3	15.5	19.6	-129bps	409bps
EBITDA per ton (₹)	1,057	996	980	828	830	765	970	1,199	958	695	924	-4.7	33.0
Interest	173	160	105	114	131	135	128	135	147	215	216	68.4	0.5
Depreciation	718	730	754	735	728	756	767	758	765	797	833	8.6	4.5
Other income	443	140	230	388	482	105	170	435	435	137	195	15.2	42.9
PBT	2,197	1,515	2,053	1,703	1,671	1,315	2,467	2,782	2,132	1,101	1,857	-24.7	68.6
Tax	512	286	967	453	527	304	813	862	450	153	396	-51.3	158.0
PAT	1,609	1,228	1,086	1,250	1,145	1,011	1,654	1,920	1,682	948	1,462	-11.6	54.2
Source: Anand Bathi Resear	rch												


Fig 8 – Per-ton ana	lysis												
(₹ / ton)	Q2 FY18	Q3 FY18	Q4 FY18	Q1 FY19	Q2 FY19	Q3 FY19	Q4 FY19	Q1 FY20	Q2 FY20	Q3 FY20	Q4 FY20	% Y/Y	% Q/Q
Realisation	4,783	4,606	4,571	4,537	4,622	4,392	4,640	4,989	4,708	4,475	4,713	1.6	5.3
EBITDA	1,057	996	980	828	830	765	970	1,199	958	695	924	-4.7	33.0
Sales volumes (m tons)	2.15	2.27	2.74	2.61	2.47	2.75	3.29	2.70	2.72	2.84	2.93	-10.9	3.1
Costs													
Raw material	811	810	834	781	723	720	754	796	777	819	892	18.3	9.0
Power & Fuel	802	751	795	980	956	987	893	984	996	911	868	-2.8	-4.8
Freight	979	995	1,064	1,123	1,095	1,015	1,050	1,040	990	996	1,037	-1.3	4.1
Staff	369	334	270	314	340	296	250	327	362	339	288	15.2	-15.0
Other expenditure	701	647	617	601	651	600	624	696	668	700	790	26.6	12.8
Source: Anand Rathi Resear	rch												


# Other key highlights

## **Revenue growth**

Impacted by the lockdown imposed in March, Ramco's Q4 sales volumes declined 11% y/y to 2.93m tons, resulting in overall revenue dipping 9% y/y to ₹13.8bn. However, realisations grew 1.6% y/y to ₹4,713/ton. In FY20, the wind-power division generated 226.8m units (242.6m units a year ago), and ₹580.7m in revenue.

New urban construction is minimal; construction is primarily seen in rural areas. The company's projects and infrastructure divisions have huge challenges due to non-availability of workers, logistics constraints, uncertain imports and stress in the financial sector. The company expects demand for cement to return to normal, based on further relaxations announced by the Central and state governments in course of time. It expects to reach its earlier levels in the medium to long term when restrictions are lifted.







# **Operating performance**

The company reported ₹2.7bn EBITDA (down 15% y/y). EBITDA/ton (blended) declined ~5% y/y to ₹924 (₹970 a year ago, ₹695 the quarter prior). This was mainly due to the restrained topline, a 13% y/y rise in other expenditure, and 3% in staff costs. Raw material cost per ton increased 18.3% y/y. However, some relief in costs was seen from lower pet-coke prices and savings in logistics, leading to per-ton power &fuel and freight costs declining 2.8% and 1.3% y/y respectively.

Adjusted PAT declined 12% y/y to ₹1,462m due to the subdued operational performance and higher interest expense (up 68% y/y) and depreciation expense (up 9% y/y), set off by other income increasing 15% y/y and by lower tax expense.





# **Capex**

Expansion of the 1m-ton grinding unit at Kolaghat (West Bengal) was completed on 26<sup>th</sup> Sep'19 and the 1.05m-ton grinding unit at Vishakhapatnam (AP) in Mar'20. The remaining on-going capacity-expansion is on schedule but for delays caused by the exit of labourers from project sites due to Covid-19. The company has so far incurred ₹19.2bn on capacity expansion. The balance capex to be incurred for ongoing capacity expansion would be ₹13.8bn. Further, due to the time over-run, the cost of the ongoing capacity expansion is expected to increase. Capacity details and budgeted capex are:

Plant	Capacity (m tpa)	Budgeted capex (₹ bn)	Expected commissioning
Kurnool, AP	2.25 (clinker) + 1 (cement) + 12.15MW WHRS + 18MW CPP + railway sliding	15	Mar''21
Jayanthipuram, AP	1.5 (clinker) + 27MW WHRS	7.4	Mar"21
Vishakhapatnam	1.05	2.5	Commissioned in Mar'20
Hardisarpur, Odisha	1	5.15	Aug'20
West Bengal	1.1	4.25	Commissioned in Sep'19
	1.1		Commissione

These expansions would be financed mostly through borrowings and internal accruals. This would lead to the company's business expanding in the coastal districts of AP, Odisha and West Bengal, and the north-eastern states.

Borrowings at 31st Mar'20 were ₹30.24bn (incl. current maturities of ₹3.92bn). Of this, ₹15.5bn are from banks; ₹3.95bn from debentures. Soft/interest-free loans of ₹2.78bn are long term. The average cost of interest on borrowing is 7.34%

# **Valuations**


The Covid'19-compelled lockdown from Mar'20 hurt Ramco's Q4. Its revenue/EBITDA/PAT declined 9%/15%/12%. The Vishakhapatnam expansion was completed in Mar. Labour unavailability, however, delayed the remaining expansions by 3-5 months. With demand in the near term expected to be sluggish, we expect profitability to improve on steady pricing, lower fuel prices and new capacity commissioning.

We maintain our Buy rating, at a target price of ₹748, based on 16x FY22e EV/EBITDA.

# **Change in estimates**

We have broadly maintained our FY21 estimates and increased FY22 EBITDA and PAT respectively 6.6% and 7.6% because of the improving operating efficiency and higher fixed-cost absorption on the new capacity commissioning.

Fig 14 - Change in estimates Old Variance % (₹m) FY21e FY22e FY21e FY22e FY21e FY22e 49,255 50,672 Sales 59,131 58,872 (2.8)0.4 EBITDA 9,214 12,717 9,179 11,929 0.4 6.6 PAT 7.6 4,195 6,372 4,087 5,923 2.6 Source: Anand Rathi Research





	СМР	P/E		EV / EBITDA		EV / ton (\$)	
	(₹)	FY21e	FY22e	FY21e	FY22e	FY21e	FY22e
Ramco Cement	645	36.2	23.8	20.2	14.1	117	113
Birla Corp.	575	18.1	13.0	8.0	6.6	59	49
Dalmia Bharat	598	NA	194.4	8.2	6.7	82	69
Deccan Cement	278	14.0	7.6	6.5	3.8	20	19
Heidelberg Cement	173	21.7	14.8	10.0	7.6	78	73
India Cement	130	NA	29.2	12.9	9.7	61	62
JK Cement	1,396	29.1	18.5	14.0	10.1	110	104
JK Lakshmi	255	43.0	12.7	9.9	5.6	46	39
Mangalam Cement	196	14.2	8.0	6.9	4.9	37	34
NCL Indus	75	11.2	5.9	5.2	3.6	26	23
Orient Cement	73	95.6	21.6	9.4	7.0	42	40
Prism Johnson	47	NA	28.3	10.8	7.8	51	48
Sanghi Industries	26	NA	16.0	13.3	8.5	38	39
Source: Anand Rathi Research							

# Risk


- Extension of the lockdown
- Profitability may be curbed by a rise in prices of pet-coke and diesel.

#### **Appendix**

#### **Analyst Certification**

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies



### **Anand Rathi Ratings Definitions**

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps ( <us\$1bn)< td=""><td>&gt;25%</td><td>5-25%</td><td>&lt;5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	

#### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views, While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL,

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

#### Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No	
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No	

#### Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- © 2019. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.